866-997-4948(US-Canada Toll Free)

Bromodomain Testis Specific Protein (Cancer/Testis Antigen 9 or RING3 Like Protein or BRDT) - Pipeline Review, H1 2017

Published By :

Global Markets Direct

Published Date : Jun 2017

Category :

Pharmaceutical

No. of Pages : 34 Pages

Bromodomain Testis Specific Protein (Cancer/Testis Antigen 9 or RING3 Like Protein or BRDT) - Pipeline Review, H1 2017

Summary

Bromodomain Testis Specific Protein (Cancer/Testis Antigen 9 or RING3 Like Protein or BRDT) - Bromodomain testis-specific protein is a protein encoded by the BRDT gene. It plays a role in meiotic and post-meiotic cells by binding to acetylated histones at the promoter of specific meiotic and post-meiotic genes, facilitating their activation at the appropriate time. It binds to hyperacetylated histones and participates in their general removal from DNA.

Bromodomain Testis Specific Protein (Cancer/Testis Antigen 9 or RING3 Like Protein or BRDT) pipeline Target constitutes close to 5 molecules. Out of which approximately 5 molecules are developed by Companies. The molecules developed by companies in Phase II and Phase I stages are 1 and 4 respectively. Report covers products from therapy areas Oncology which include indications Myelodysplastic Syndrome, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Multiple Myeloma (Kahler Disease), Myelofibrosis, Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia, Solid Tumor, Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), B-Cell Non-Hodgkin Lymphoma, Breast Cancer, Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia), Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma), Lymphoma, Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Myeloproliferative Disorders, NUT Midline Carcinoma (NMC or Nuclear Protein in Testis Midline Carcinoma), Refractory Multiple Myeloma and Relapsed Multiple Myeloma.

The latest report Bromodomain Testis Specific Protein - Pipeline Review, H1 2017, outlays comprehensive information on the Bromodomain Testis Specific Protein (Cancer/Testis Antigen 9 or RING3 Like Protein or BRDT) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Bromodomain Testis Specific Protein (Cancer/Testis Antigen 9 or RING3 Like Protein or BRDT) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Bromodomain Testis Specific Protein (Cancer/Testis Antigen 9 or RING3 Like Protein or BRDT)
- The report reviews Bromodomain Testis Specific Protein (Cancer/Testis Antigen 9 or RING3 Like Protein or BRDT) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Bromodomain Testis Specific Protein (Cancer/Testis Antigen 9 or RING3 Like Protein or BRDT) targeted therapeutics and enlists all their major and minor projects
- The report assesses Bromodomain Testis Specific Protein (Cancer/Testis Antigen 9 or RING3 Like Protein or BRDT) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Bromodomain Testis Specific Protein (Cancer/Testis Antigen 9 or RING3 Like Protein or BRDT) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Bromodomain Testis Specific Protein (Cancer/Testis Antigen 9 or RING3 Like Protein or BRDT)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Bromodomain Testis Specific Protein (Cancer/Testis Antigen 9 or RING3 Like Protein or BRDT) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Bromodomain Testis Specific Protein (Cancer/Testis Antigen 9 or RING3 Like Protein or BRDT) - Overview
Bromodomain Testis Specific Protein (Cancer/Testis Antigen 9 or RING3 Like Protein or BRDT) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Bromodomain Testis Specific Protein (Cancer/Testis Antigen 9 or RING3 Like Protein or BRDT) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Bromodomain Testis Specific Protein (Cancer/Testis Antigen 9 or RING3 Like Protein or BRDT) - Companies Involved in Therapeutics Development
F. Hoffmann-La Roche Ltd
Forma Therapeutics Inc
Incyte Corp
Bromodomain Testis Specific Protein (Cancer/Testis Antigen 9 or RING3 Like Protein or BRDT) - Drug Profiles
CPI-0610 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
FT-1101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
INCB-54329 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RG-6146 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ZEN-3694 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Bromodomain Testis Specific Protein (Cancer/Testis Antigen 9 or RING3 Like Protein or BRDT) - Discontinued Products
Bromodomain Testis Specific Protein (Cancer/Testis Antigen 9 or RING3 Like Protein or BRDT) - Product Development Milestones
Featured News & Press Releases
Jun 05, 2017: Zenith Announces Issuance of Patent for ZEN-3694 and Presentation Details at BIO International Convention
Dec 14, 2016: Zenith Announces Initiation of Phase 1b Clinical Combination Trial for ZEN-3694
Jun 15, 2016: Zenith Announces Dosing of First Patient in Phase 1 Clinical Trial and Corporate Update Webcast Details
Jan 12, 2016: FORMA Therapeutics Enrolls First Patient in Phase 1 Study of FT-1101 in Advanced Hematological Malignancies
Nov 20, 2013: Tensha Therapeutics Announces First Clinical Trial of BET Bromodomain Inhibitor TEN-010 for Treatment of Cancer
Sep 10, 2013: Constellation Pharmaceuticals Initiates Clinical Development of CPI-0610, a Novel BET Protein Bromodomain Inhibitor, in Patients with Lymphoma
Nov 29, 2012: Cancer Drug Shows Promise In Eradicating Latent HIV Infection, Research Shows
Aug 16, 2012: Researchers Develop Potential Male Contraceptive Pill
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development by Stage of Development, H1 2017
Number of Products under Development by Therapy Areas, H1 2017
Number of Products under Development by Indication, H1 2017
Number of Products under Development by Companies, H1 2017
Products under Development by Companies, H1 2017
Products under Development by Companies, H1 2017 (Contd..1), H1 2017
Number of Products by Stage and Mechanism of Actions, H1 2017
Number of Products by Stage and Route of Administration, H1 2017
Number of Products by Stage and Molecule Type, H1 2017
Pipeline by F. Hoffmann-La Roche Ltd, H1 2017
Pipeline by Forma Therapeutics Inc, H1 2017
Pipeline by Incyte Corp, H1 2017
Discontinued Products, H1 2017

List of Figures
Number of Products under Development by Stage of Development, H1 2017
Number of Products under Development by Top 10 Indications, H1 2017
Number of Products by Stage and Mechanism of Actions, H1 2017
Number of Products by Routes of Administration, H1 2017
Number of Products by Stage and Routes of Administration, H1 2017
Number of Products by Stage and Molecule Type, H1 2017

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *